50693-78-2

Basic information

• Product Name: 4-METHYL-2-PIPERAZIN-1-YL-QUINOLINE
• Synonyms: ART-CHEM-BB B028520;AKOS BB-6900;AKOS B028520;4-METHYL-2-PIPERAZIN-1-YL-QUINOLINE;TIMTEC-BB SBB007335
• CAS NO: 50693-78-2
• Molecular Formula: C₁₄H₁₇N₃
• Molecular Weight: 227.3
• Mol File: 50693-78-2.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 432 °C at 760 mmHg
• Flash Point: 215 °C
• Appearance: /
• Density: 1.128
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 4-METHYL-2-PIPERAZIN-1-YL-QUINOLINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-METHYL-2-PIPERAZIN-1-YL-QUINOLINE(50693-78-2)
• EPA Substance Registry System: 4-METHYL-2-PIPERAZIN-1-YL-QUINOLINE(50693-78-2)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 50693-78-2(Hazardous Substances Data)

Usage

General Description

4-Methyl-2-piperazin-1-yl-quinoline, also known as MPQ, is a chemical compound with the molecular formula C16H17N3. It is a piperazine-based small molecule that is often used as a fluorescent probe in biomedical imaging studies. MPQ has been shown to have potential therapeutic benefits, including anti-cancer and anti-inflammatory properties, and has been the subject of research for its potential use in treating various diseases. Additionally, MPQ has been investigated for its role in targeting specific receptors in the brain and is being studied for its potential in the development of new drugs for neurological disorders. Overall, MPQ is a versatile compound with a range of potential applications in the fields of medicine and biomedical research.

Upstream product

• 62-53-3 aniline 
• 607-66-9 4-methyl-1,2-dihydroquinolin-2-one 
• 102-01-2 N-phenylacetoacetamide 
• 110-85-0 piperazine 
• 634-47-9 2-chloro-4-methylquinoline 

Downstream Products

• 710328-36-2 4-{4-methyl-6-[3-(4-trifluoromethoxy-phenyl)-acryloylamino]-quinolin-2-yl}-piperazine-1-carboxylic acid tert-butyl ester 

Relevant articles and documents

Developing Inhibitors of the p47phox-p22phox Protein-Protein Interaction by Fragment-Based Drug Discovery

Nicotinamide adenine dinucleotide phosphate oxidase isoform 2 is an enzyme complex, which generates reactive oxygen species and contributes to oxidative stress. The p47phox-p22phox interaction is critical for the activation of the catalytical NOX2 domain, and p47phox is a potential target for therapeutic intervention. By screening 2500 fragments using fluorescence polarization and a thermal shift assay and validation by surface plasmon resonance, we found eight hits toward the tandem SH3 domain of p47phox (p47phoxSH3A-B) with KD values of 400-600 μM. Structural studies revealed that fragments 1 and 2 bound two separate binding sites in the elongated conformation of p47phoxSH3A-B and these competed with p22phox for binding to p47phoxSH3A-B. Chemical optimization led to a dimeric compound with the ability to potently inhibit the p47phoxSH3A-B-p22phox interaction (Ki of 20 μM). Thereby, we reveal a new way of targeting p47phox and present the first report of drug-like molecules with the ability to bind p47phox and inhibit its interaction with p22phox.

ANTHELMINTIC COMPOUNDS AND COMPOSITIONS AND METHOD OF USING THEREOF

The present invention relates to novel anthelmintic compounds of formula (I) below: wherein Y and Z are independently a bicyclic carbocyclic or a bicyclic heterocyclic group, or one of Y or Z is a bicyclic carbocyclic or a bicyclic heterocyclic group and the other of Y or Z is alkyl, alkenyl, alkynyl, cycloalkyl, phenyl, heterocyclyl or heteroaryl, and variables X1, X2, X3, X4, X5, X6, X7 and X8 are as defined herein. The invention also provides for veterinary compositions comprising the anthelmintic compounds of the invention, and their uses for the treatment and prevention of parasitic infections in animals.

6-Acylamino-2-aminoquinolines as potent melanin-concentrating hormone 1 receptor antagonists. Identification, structure-activity relationship, and investigation of binding mode

Novel 6-acylamino-2-aminoquinoline melanin-concentrating hormone 1 receptor (MCH1R) antagonists were identified by sequential in silico screening with 3D pharmacophore models derived from a series of benzamide antagonists. The structure-activity relationship exploration by synthesis of analogues found structural demands around the western part of the compounds to be quite specific, whereas much structural freedom was found in the eastern part. While these compounds in general suffered from poor solubility properties, the 4-trifluoromethoxy-phenoxyacetamide western appendage provided a favorable combination of activity and solubility properties. The amine in the eastern appendage, originally required by the pharmacophore model and believed to interact with Asp123 in transmembrane 3 of MCH1R, could be removed without diminishing affinity or functional activity of the compounds. Docking studies suggested that the Asp123 interacts preferentially with the nitrogen of the central quinoline. Synthesis and testing of specific analogues supported our revised binding mode hypothesis.